Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HER2-CD3-Fc mRNA-LNPs
- Development stage
- Preclinical
- Lead developer
- ProMab Biotechnologies
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intratumoral
01
Overview
HER2-CD3-Fc mRNA-LNPs is an experimental therapeutic consisting of lipid nanoparticles (LNPs) encapsulating messenger RNA (mRNA) that encodes a novel bispecific antibody (bsAb). This bsAb is designed with binding domains for the tumor-associated antigen HER2 (Human Epidermal Growth Factor Receptor 2) and the T-cell marker CD3, along with an Fc region for stability and extended half-life. Upon administration, the LNPs transfect host cells, which then express and secrete the bispecific antibody. The secreted bsAb facilitates the recruitment and activation of T cells against HER2-overexpressing tumor cells, inducing potent T-cell-directed cytotoxicity and the secretion of inflammatory cytokines such as IFN-γ and TNF-α. Preclinical studies have demonstrated significant antitumor activity and complete tumor growth blockage in various HER2-positive cancer models, including ovarian, breast, and lung cancers.
- Other names
- HER2-CD3-Fc mRNA-LNPHER-2-CD3-Fc mRNA-LNPHER 2-CD3-Fc mRNA-LNPmRNA-LNP encoding HER2-CD3-Fc bispecific antibody
02
Targets
CD3 (T-cell surface glycoprotein CD3)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on HER2-CD3-Fc mRNA-LNPs.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HER2-CD3-Fc mRNA-LNPs.